Compare Aptiv PLC (APTV) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Johnson & Johnson — how do they compare? Aptiv PLC trades at $48.52 (market cap $10.30B), while Johnson & Johnson trades at $260.8 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 60.8× Aptiv PLC's market cap, and Johnson & Johnson pays a 2.06% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | JNJ | |
|---|---|---|
Market Cap | $10.30B | $626.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $267.24 |
52-Week Low | $46.30 | $172.78 |
Enterprise Value | $15.23B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $48.38, down 2.87% on the day, reflecting bearish technical signals and recent guidance cuts. The stock shows strong valuation metrics with a P/E of 22.45 and P/S of 0.52, but profitability is weak with a net margin of 1.07%. Recent Q2 2026 earnings beat estimates, but the company lowered its full-year outlook due to China demand issues and launch delays, pressuring investor sentiment.
The outlook is mixed: low valuation and analyst consensus of $70.09 target suggest upside, but near-term execution risks and cash flow pressures create uncertainty. Investment opportunity hinges on margin recovery and China market stabilization, while risks include sustained guidance cuts and competitive pressures in automotive technology.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
